Role of HER2/neu in tumor progression and therapy.
暂无分享,去创建一个
M. Campiglio | S. Ménard | S. Pupa | E. Tagliabue | P. Casalini | S. Pupa
[1] Piero Musiani,et al. Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. , 2004, Cancer research.
[2] M. Campiglio,et al. Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (‘Iressa’) is independent of EGFR expression level , 2004, Journal of cellular physiology.
[3] D. Larsimont,et al. Evaluation of HER-2/NEU Protein Expression in Breast Cancer by Immunohistochemistry: An Interlaboratory Study Assessing the Reproducibility of HER-2/NEU Testing , 2002, Breast Cancer Research and Treatment.
[4] O. Nanni,et al. Prognostic significance of biologic markers in node-negative breast cancer patients: a prospective study , 2000, Breast Cancer Research and Treatment.
[5] F. Kern,et al. MCF-7 breast cancer cells overexpressing transfectedc-erbB-2 have anin vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivityin vivo , 1995, Breast Cancer Research and Treatment.
[6] A. Ullrich,et al. Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic , 1991, Journal of Clinical Immunology.
[7] S. Eccles,et al. Differential modulation of proliferation, matrix metalloproteinase expression and invasion of human head and neck squamous carcinoma cells by c-erbB ligands , 2004, Clinical & Experimental Metastasis.
[8] M. Campiglio,et al. Role of HER2 in wound-induced breast carcinoma proliferation , 2003, The Lancet.
[9] G. Sala,et al. Feedback inhibition by RALT controls signal output by the ErbB network , 2003, Oncogene.
[10] J. Kim,et al. The Role of ErbB2 Signaling in the Onset of Terminal Differentiation of Oligodendrocytes In Vivo , 2003, The Journal of Neuroscience.
[11] M. Campiglio,et al. Role of proliferation in HER2 status predicted response to doxorubicin , 2003, International journal of cancer.
[12] D. Stern,et al. Neural and mammary gland defects in ErbB4 knockout mice genetically rescued from embryonic lethality , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[13] S. Ménard,et al. HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Gottfried Konecny,et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. , 2003, Journal of the National Cancer Institute.
[15] Barbara L. Smith,et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] H. Kato,et al. Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non‐small cell lung cancer , 2003, International journal of cancer.
[17] P. Ohashi,et al. Making and breaking tolerance. , 2002, Current opinion in immunology.
[18] S. Ménard,et al. Prevention of spontaneous mammary adenocarcinoma in HER‐2/neu transgenic mice by foreign DNA , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[19] A. Lipton,et al. Restoration of estrogen responsiveness by blocking the HER-2/neu pathway. , 2002, Oncology reports.
[20] Thomas Dittmar,et al. Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c‐erbB‐2 receptor via epidermal growth factor receptor , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[21] M. Bui,et al. Prognostic and predictive value of HER2/neu oncogene in breast cancer , 2002, Microscopy research and technique.
[22] Jayanta Debnath,et al. The Role of Apoptosis in Creating and Maintaining Luminal Space within Normal and Oncogene-Expressing Mammary Acini , 2002, Cell.
[23] Anthony Rhodes,et al. Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. , 2002, American journal of clinical pathology.
[24] K. Miller,et al. HER-2/neu expression in germ cell tumours , 2002, Journal of clinical pathology.
[25] M. Wolter,et al. Gene amplification and protein overexpression of c-erb-b2 in Barrett carcinoma and its precursor lesions. , 2002, American journal of clinical pathology.
[26] N. Tsavaris,et al. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes , 2002, British Journal of Cancer.
[27] M. Raffeld,et al. Her-2/neu expression and gene amplification in gastrinomas: correlations with tumor biology, growth, and aggressiveness. , 2002, Cancer research.
[28] Guido Forni,et al. Antitumor vaccines: is it possible to prevent a tumor? , 2002, Cancer Immunology, Immunotherapy.
[29] Carmen Birchmeier,et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[30] Peter A Kaufman,et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. , 2002, Journal of the National Cancer Institute.
[31] Greg Yothers,et al. Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience. , 2002, Journal of the National Cancer Institute.
[32] M. Hung,et al. Novel targets of Akt, p21(Cipl/WAF1), and MDM2. , 2002, Seminars in oncology.
[33] T. Foy,et al. Designing HER2 vaccines. , 2002, Seminars in oncology.
[34] Hermann Herbst,et al. Common Adult Stem Cells in the Human Breast Give Rise to Glandular and Myoepithelial Cell Lineages: A New Cell Biological Concept , 2002, Laboratory Investigation.
[35] J. Beneke,et al. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays. , 2002, American journal of clinical pathology.
[36] M. Cheever,et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] F. Hirsch,et al. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas , 2002, British Journal of Cancer.
[38] D. Larsimont,et al. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[39] G. Forni,et al. Prophylactic cancer vaccines. , 2002, Current opinion in immunology.
[40] D. Jäger,et al. Clinical cancer vaccine trials. , 2002, Current opinion in immunology.
[41] Lei Xu,et al. Tumour biology: Herceptin acts as an anti-angiogenic cocktail , 2002, Nature.
[42] S. Ménard,et al. Early relapse of premenopausal patients after surgery for node-positive breast carcinoma. , 2002, Breast cancer research and treatment.
[43] F. Hirsch,et al. Epidermal growth factor receptor family in lung cancer and premalignancy. , 2002, Seminars in oncology.
[44] Lyndsay N Harris,et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] M. Campiglio,et al. HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[46] Benjamin D. Smith,et al. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[47] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[48] M. Campiglio,et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[49] Y. Zeng,et al. Absence of evidence for HER2 amplification in nasopharyngeal carcinoma. , 2002, Cancer genetics and cytogenetics.
[50] J. Feldner,et al. Cancer cell motility--on the road from c-erbB-2 receptor steered signaling to actin reorganization. , 2002, Experimental cell research.
[51] J. Bartlett,et al. Gene amplification and overexpression of HER2 in renal cell carcinoma , 2002, BJU international.
[52] G. Forni,et al. Prophylactic cancer vaccines. , 2002, Current opinion in immunology.
[53] A Choudhury,et al. Cellular immunity to the Her-2/neu protooncogene. , 2002, Advances in cancer research.
[54] Piero Musiani,et al. Combined Allogeneic Tumor Cell Vaccination and Systemic Interleukin 12 Prevents Mammary Carcinogenesis in HER-2/neu Transgenic Mice , 2001, The Journal of experimental medicine.
[55] Yong Liao,et al. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation , 2001, Nature Cell Biology.
[56] S. Ménard,et al. HER2 as a Prognostic Factor in Breast Cancer , 2001, Oncology.
[57] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[58] Y. Yarden. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. , 2001, European journal of cancer.
[59] M. Bissell,et al. ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini , 2001, Nature Cell Biology.
[60] T. Benstead,et al. PROGRESS IN CLINICAL NEUROSCIENCES: Charcot-Marie-Tooth Disease and Related Inherited Peripheral Neuropathies , 2001, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[61] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[62] P. Musiani,et al. Inhibition of mammary carcinogenesis by systemic interleukin 12 or p185neu DNA vaccination in Her-2/neu transgenic BALB/c mice. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[63] M. Hung,et al. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells , 2001, Nature Cell Biology.
[64] A. Ullrich,et al. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. , 2001, Endocrine-related cancer.
[65] K. Knutson,et al. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. , 2001, The Journal of clinical investigation.
[66] S. Ménard,et al. Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] M. Campiglio,et al. HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[68] P. Stanton,et al. The value of the human epidermal growth factor receptor-2 (HER2) as a prognostic marker. , 2001, European journal of cancer.
[69] N. Rosen,et al. The Tyrosine Kinase Inhibitor ZD 1839 ( “ Iressa ” ) Inhibits HER 2-driven Signaling and Suppresses the Growth of HER 2-overexpressing Tumor Cells 1 , 2001 .
[70] Yosef Yarden,et al. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer , 2000, Oncogene.
[71] A. Aderem,et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[72] M. Kris,et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[73] Piero Musiani,et al. DNA Vaccination Against Rat Her-2/Neu p185 More Effectively Inhibits Carcinogenesis Than Transplantable Carcinomas in Transgenic BALB/c Mice1 2 , 2000, The Journal of Immunology.
[74] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[75] P. Triozzi,et al. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. , 2000, Cancer research.
[76] H. Allgayer,et al. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[77] R. Kerbel,et al. 'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. , 2000, European journal of cancer.
[78] John M. Daly,et al. ErbB2 Potentiates Breast Tumor Proliferation through Modulation of p27Kip1-Cdk2 Complex Formation: Receptor Overexpression Does Not Determine Growth Dependency , 2000, Molecular and Cellular Biology.
[79] R. Stein,et al. Evolutionary Analysis of the ErbB Receptor and Ligand Families , 2000, Journal of Molecular Evolution.
[80] A. Sacchi,et al. Cooperative Signaling between α6β4Integrin and ErbB-2 Receptor Is Required to Promote Phosphatidylinositol 3-Kinase-dependent Invasion* , 2000, The Journal of Biological Chemistry.
[81] L. Presta,et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.
[82] C. Birchmeier,et al. A Dual Role of erbB2 in Myelination and in Expansion of the Schwann Cell Precursor Pool , 2000, The Journal of cell biology.
[83] M. Campiglio,et al. Role of HER2 gene overexpression in breast carcinoma , 2000, Journal of cellular physiology.
[84] D. Talmage,et al. Cysteine-Rich Domain Isoforms of the Neuregulin-1 Gene Are Required for Maintenance of Peripheral Synapses , 2000, Neuron.
[85] S. Eccles,et al. Cell biology of lymphatic metastasis. The potential role of c-erbB oncogene signalling. , 2000, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[86] M. Colombo,et al. Antitumor vaccination: where we stand. , 2000, Haematologica.
[87] A. Sckell,et al. Targeting HER‐2/neu for active‐specific immunotherapy in a mouse model of spontaneous breast cancer , 1999, International journal of cancer.
[88] P. Caroni,et al. Peripheral nervous system defects in erbB2 mutants following genetic rescue of heart development. , 1999, Genes & development.
[89] N. Robert,et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[90] S. Ménard,et al. Correspondence re: Y. Chen et al., DNA vaccines encoding full-length or truncated neu induce protective immunity against neu-expressing mammary tumors. Cancer Res., 58: 1965-1971, 1998. , 1999, Cancer research.
[91] M. Sliwkowski,et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). , 1999, Seminars in oncology.
[92] Y. Yarden,et al. The C‐terminus of the kinase‐defective neuregulin receptor ErbB‐3 confers mitogenic superiority and dictates endocytic routing , 1999, The EMBO journal.
[93] D. Stern,et al. Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation , 1999, Oncogene.
[94] Kuo-Fen Lee,et al. Rescue of the Cardiac Defect in ErbB2 Mutant Mice Reveals Essential Roles of ErbB2 in Peripheral Nervous System Development , 1999, Neuron.
[95] R. Cardiff,et al. Elevated expression of activated forms of Neu/ErbB‐2 and ErbB‐3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer , 1999, The EMBO journal.
[96] P. Lollini,et al. Cytokine gene therapy: hopes and pitfalls. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[97] L. Esserman,et al. Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice , 1999, Cancer Immunology, Immunotherapy.
[98] S. Ménard,et al. Ectopic expression of pRb2/p130 suppresses the tumorigenicity of the c-erbB-2-overexpressing SKOV3 tumor cell line , 1999, Oncogene.
[99] P. Musiani,et al. Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12. , 1999, Cancer research.
[100] S. Ménard,et al. Target molecules for immunotherapy of inflammatory breast carcinomas. , 1998, European journal of cancer.
[101] M. Freeman,et al. An Autoregulatory Cascade of EGF Receptor Signaling Patterns the Drosophila Egg , 1998, Cell.
[102] B Fisher,et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. , 1998, Journal of the National Cancer Institute.
[103] D A Berry,et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. , 1998, Journal of the National Cancer Institute.
[104] J. Fletcher,et al. Multivariate analysis of prognostic factors in lymph node negative breast cancer , 1998 .
[105] R. Derynck,et al. Activation and function of the epidermal growth factor receptor and erbB-2 during mammary gland morphogenesis. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[106] D. Riethmacher,et al. The ErbB2 and ErbB3 receptors and their ligand, neuregulin-1, are essential for development of the sympathetic nervous system. , 1998, Genes & development.
[107] David C. Lee,et al. Dynamic expression and activation of ERBB receptors in the developing mouse mammary gland. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[108] S. Martino,et al. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[109] G. Frantz,et al. ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice. , 1997, Development.
[110] S. Ménard,et al. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[111] D. Riethmacher,et al. Severe neuropathies in mice with targeted mutations in the ErbB3 receptor , 1997, Nature.
[112] C. Birchmeier,et al. Isoform-specific expression and function of neuregulin. , 1997, Development.
[113] D. Slamon,et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[114] N. Hynes,et al. ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.
[115] Dihua Yu,et al. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. , 1997, Cancer research.
[116] M. Cheever,et al. HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. , 1997, Advances in cancer research.
[117] M. Miloso,et al. Post-transcriptional Control Regulates Transforming Growth Factor α in the Human Carcinoma KB Cell Line* , 1996, The Journal of Biological Chemistry.
[118] M. Campiglio,et al. Laminin activates the p185HER2 oncoprotein and mediates growth inhibition of breast carcinoma cells. , 1996, British Journal of Cancer.
[119] Y. Yarden,et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor , 1996, Molecular and cellular biology.
[120] W. Muller,et al. Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization and activation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[121] G. Clinton,et al. Her-2/Neu and Breast Cancer. , 1996 .
[122] L. Bobrow,et al. Relationship of histologic grade, c-erbB-2 expression, and inflammatory infiltrate to prognosis in carcinoma of the breast. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[123] E. Raz,et al. Immunostimulatory DNA Sequences Necessary for Effective Intradermal Gene Immunization , 1996, Science.
[124] L. Theill,et al. Neuregulins with an Ig-like domain are essential for mouse myocardial and neuronal development. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[125] Y. Yarden,et al. ErbB‐2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. , 1996, The EMBO journal.
[126] S. Ménard,et al. Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[127] Kuo-Fen Lee,et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development , 1995, Nature.
[128] Rüdiger Klein,et al. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor , 1995, Nature.
[129] R. Lupu,et al. Bidirectional interactions between the estrogen receptor and the c‐erbB‐2 signaling pathways: Heregulin inhibits estrogenic effects in breast cancer cells , 1995, International journal of cancer.
[130] W. Birchmeier,et al. Sequential requirement of hepatocyte growth factor and neuregulin in the morphogenesis and differentiation of the mammary gland , 1995, The Journal of cell biology.
[131] G. Mann,et al. A mutation in the epidermal growth factor receptor in waved-2 mice has a profound effect on receptor biochemistry that results in impaired lactation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[132] M. Campiglio,et al. Colocalization of the p185HER2 oncoprotein and integrin α6β4 in Calu‐3 lung carcinoma cells , 1994 .
[133] N. Copeland,et al. The mouse waved-2 phenotype results from a point mutation in the EGF receptor tyrosine kinase. , 1994, Genes & development.
[134] M. Bissell,et al. The tumor-promoting effect of wounding: a possible role for TGF-beta-induced stromal alterations. , 1994, Critical reviews in oncogenesis.
[135] Wei Chen,et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. , 1994, Cancer research.
[136] S. Ménard,et al. Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients. , 1993, Cancer research.
[137] R. Cardiff,et al. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[138] L. Presta,et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[139] D. Slamon,et al. Radiolabeled antibody targeting of the HER-2/neu oncoprotein. , 1992, Cancer research.
[140] S. Ménard,et al. Prognostic significance of her‐2/neu expression in breast cancer and its relationship to other prognostic factors , 1991, International journal of cancer.
[141] M. Kraus,et al. Oncogenic potential of erbB-2 in human mammary epithelial cells. , 1991, Oncogene.
[142] A. Ullrich,et al. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. , 1991, Growth regulation.
[143] Paul W. Sternberg,et al. The let-23 gene necessary for Caenorhabditis elegans vulval induction encodes a tyrosine kinase of the EGF receptor subfamily , 1990, Nature.
[144] C. Cordon-Cardo,et al. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. , 1990, Oncogene.
[145] A. Ullrich,et al. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. , 1990, Cancer research.
[146] M. Kraus,et al. Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[147] E. Scanlon,et al. The influence of surgical trauma on experimental metastasis , 1989, Cancer.
[148] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[149] A. Ullrich,et al. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor , 1989, Molecular and cellular biology.
[150] C R King,et al. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. , 1987, Science.
[151] P. Seeburg,et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. , 1985, Science.
[152] P. Seeburg,et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells , 1984, Nature.
[153] M. Winget,et al. p 185 HER 2 Monoclonal Antibody Has An ( iproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor , 2022 .
[154] L. Presta,et al. Humanization of an anti-p 185 HER 2 antibody for human cancer therapy ( antibody engineering / site-directed mutagenesis / c-erbB2 / neu ) , 2022 .